Biller Jonathan

EVP & Chief Legal Officer Jonathan Biller sold 3,720 shares at blended average $484.18 for $1,801,160.88 on VRTX

Jonathan Biller, EVP and Chief Legal Officer, executed 2 separate sales totaling 3,720 shares for $1,801,160.88 across February 17-18, 2026, reducing his holdings by 19.1% to 15,748 shares. The sales occurred near the 52-week high (current price $469.27 is 8.7% below the $513.76 peak), and at prices ($484.18 blended average) that remain well above the current market level. His prior 2 measurable sales at VRTX (February 2025) both produced negative 90-day returns (-3.2% and -4.5%), indicating a consistent pattern of well-timed exits at this ticker over the past year. The company reports solid fundamentals—$3.1B quarterly revenue, $1.1B net income, and 8.9% annual growth—with a 14.60 P/E that does not suggest distress, yet the insider's tactical execution and sustained sell pattern warrant attention to near-term price movements.

EVP Jonathan Biller sold 1.9K VRTX shares at $460.43; holds 20.8K post-sale. 2 of 3 prior VRTX sells were well-timed at 90-day mark.

Jonathan Biller, EVP and Chief Legal Officer, sold 1,925 shares of VERTEX PHARMACEUTICALS at $460.43, reducing his holdings by 8.5% to 20,819 shares. His prior trade history at VRTX shows a pattern of well-timed sales: 2 of his 3 prior VRTX sales were followed by stock declines at the 90-day mark, with negative 90-day returns of -3.2% and -4.5% respectively. The stock is currently down 9.5% from its 52-week high of $513.76, trading at $465.02. While his cross-ticker track record shows a 90-day well-timed sell rate of 66.67%, his same-ticker performance at VRTX is the more relevant benchmark, showing a demonstrated pattern of selling into price strength before subsequent weakness.

EVP and Chief Legal Officer Jonathan Biller sold 1,657 shares of VRTX at $455.06 for $754,034.42 on 2025-02-18.

Jonathan Biller, EVP and Chief Legal Officer, sold 1,657 shares at $455.06, reducing his holdings by 8.6% to 17,606 shares. The transaction occurred when VRTX was trading below its 52-week high by 8.7% and has since appreciated 11.8% in the 30 days following the sale. His prior sell at this ticker on 2024-02-12 delivered a positive 90-day return of +1.0%, indicating his past sales at VRTX have not preceded declines. The company reported $2.8B in quarterly revenue with 11.7% annual growth and $1.0B in net income, though it was unprofitable on a full-year basis, presenting a mixed fundamental picture.

EVP & CLO Jonathan Biller sells 3,433 shares of VRTX at $459.87; retains 16,330 shares post-transaction.

Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals, executed an open-market sale of 3,433 shares at $459.87 on 2025-02-11, reducing his holdings by -17.4% from 19,763 to 16,330 shares and generating $1,578,733.71 in proceeds. At his prior VRTX sale on 2024-02-12, the stock posted a +1.0% 90-day return, indicating the earlier sell did not precede a decline. The stock traded at $459.87 on the sale date and currently sits at $453.20, down 12.3% from its 52-week high of $516.74 but up 9.6% over the past 30 days. Vertex reported $2.8B quarterly revenue with net income of $1.0B and a 10.5% annual growth rate, supporting a $116.7B market cap at a 32.26 P/E ratio. The sale represents a single, discretionary open-market transaction without a scheduled trading plan disclosed.